Correlation Between Nuvalent and Revance Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Nuvalent and Revance Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nuvalent and Revance Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Nuvalent and Revance Therapeutics,, you can compare the effects of market volatilities on Nuvalent and Revance Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nuvalent with a short position of Revance Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nuvalent and Revance Therapeutics,.

Diversification Opportunities for Nuvalent and Revance Therapeutics,

0.14

Correlation Coefficient

Nuvalent  Revance Therapeutics,

Average diversification

The 3 months correlation between Nuvalent and Revance is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Nuvalent and Revance Therapeutics, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Revance Therapeutics, and Nuvalent is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nuvalent are associated (or correlated) with Revance Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Revance Therapeutics, has no effect on the direction of Nuvalent i.e., Nuvalent and Revance Therapeutics, go up and down completely randomly.

Pair Corralation between Nuvalent and Revance Therapeutics,

Given the investment horizon of 90 days Nuvalent is expected to under-perform the Revance Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Nuvalent is 1.35 times less risky than Revance Therapeutics,. The stock trades about -0.02 of its potential returns per unit of risk. The Revance Therapeutics, is currently generating about 0.2 of returns per unit of risk over similar time horizon. If you would invest  306.00  in Revance Therapeutics, on December 29, 2024 and sell it today you would earn a total of  59.00  from holding Revance Therapeutics, or generate 19.28% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	44.26%
Values	Daily Returns

Nuvalent  vs.  Revance Therapeutics,

Nuvalent

Risk-Adjusted Performance

Very Weak

Over the last 90 days Nuvalent has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Nuvalent is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors.

Revance Therapeutics,

Risk-Adjusted Performance

Good

Over the last 90 days Revance Therapeutics, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather unsteady basic indicators, Revance Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Nuvalent and Revance Therapeutics,

The main advantage of trading using opposite Nuvalent and Revance Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nuvalent position performs unexpectedly, Revance Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Revance Therapeutics, will offset losses from the drop in Revance Therapeutics,'s long position.

The idea behind Nuvalent and Revance Therapeutics, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.